Related news:
The copycat brands that are replacing Ozempic in Russia - Healthy Returns: Ozempic helps curb alcohol use in new study -- and doctors are concerned about telehealth GLP-1s - Ozempic and Wegovy officially moved off FDA's drug shortage list - Ozempic, Eliquis, Keytruda: The 8 top-selling drugs of 2024 - Strongest evidence yet that Ozempic and Wegovy reduce alcohol intake - Wegovy and Ozempic stars dim amid overuse concerns - Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy - Zepbound sales double, tariffs could hit Ozempic, and Pfizer on RFK Jr.: Pharma news roundup - Ozempic has curbed the obesity crisis. Has it killed the joy of food? - The weight-loss drugs being tested in 2025: will they beat Ozempic?
Ozempic (semaglutide) injection for Type 2 Diabetes
Bookmark
ShareOzempic (semaglutide) injection for Type 2 Diabetes is a company. It is located in the United States. The company is part of the Health Care sector.
Key facts
- country: United States
- sector: Health Care
Classified as: organization
Business
Ozempic (semaglutide) injection for Type 2 Diabetes is one of the companies in the United States, companies in Health Care and 3,466,499 companies in our database.
- Employees:
Try Pro to see estimates
- Revenues:
Try Pro to see estimates
Stocks from Ozempic (semaglutide) injection for Type 2 Diabetes:
Talking Points:
- Ozempic® (semaglutide) injection for Type 2 Diabetes
- Ozempic® (semaglutide) injection is a once-weekly GLP-1 RA medicine that, along with diet and exercise, may help improve blood sugar in adults with type 2 diabetes. Read Important Safety Information, including Boxed Warning.
Learn more about talking points
